Opioid Addiction: A Crisis Fueled by Stigma

Stigma as a Core Driver of the Crisis

• Dr. Kelly Clark defines stigma as "discrimination and prejudice" rooted in the misconception that addiction is a character flaw rather than a chronic brain disease.
• Gary Mendel of Shatterproof notes that while the federal government allocated $8 billion to the opioid crisis in 2018-2019, zero dollars were directly designated to fighting stigma.
• Mendel's research identifies that seven of the nine primary drivers of the opioid epidemic are fueled by stigma.
• Dr. Nora Volkow highlights a two-tiered stigma: "no-fault" victims of prescription opioid addiction are treated differently from those perceived as having "voluntary" addictions, despite both involving prefrontal cortex impairment that compromises decision-making.
• Current public perception remains polarized, with 44% of Americans believing addiction is a result of a lack of effort, while 43% view it as a chronic illness.
• Mendel cites the specific impact of this perception on families, noting that 80% of Americans refuse to associate socially with a friend, coworker, or neighbor if they knew that person had an addiction, even if that person was successfully treated.

Proposed Solutions and Strategic Shifts

• Shatterproof, in partnership with McKinsey, developed a seven-point plan to reduce stigma, focusing on:
  • Establishing a central coordinating organization (similar to Tobacco Free Kids).
  • Implementing low-cost action items in education, policy, and language.
  • Humanizing addiction through stories that normalize individuals living with substance use disorders (e.g., successful professionals, parents, and coaches).
  • Demonstrating the effectiveness of evidence-based treatment to counter the belief that recovery is impossible.
• Dr. Andrei Ostrovsky argues that public policy must shift from viewing addiction as a criminal justice issue to a chronic disease model, specifically within the prison system.
• A study in Rhode Island involving opioid-dependent inmates leaving incarceration showed that offering medication options (methadone, buprenorphine, or extended-release naltrexone) led to a significant decrease in overdose deaths within six months of release.
• Dr. Clark emphasizes that employers are critical levers for change, as 30 million employees work for just the 1,000 largest U.S. companies; these employers must demand "real" networks of board-certified addiction physicians rather than "phantom" networks.
• Dr. Volkow advocates for a massive budget reallocation, noting NIDA's budget ($1.25 billion) is significantly lower than those for cancer ($7 billion) or heart disease ($4.25 billion), despite higher prevalence of substance use disorders.

Policy Levers and Systemic Barriers

• The X-waiver requirement for prescribing buprenorphine is identified as a stigma-inducing logistical barrier that restricts the number of patients a physician can treat, despite the medication being as routine as prescribing insulin for diabetes.
• Providers often deny medication-assisted treatment (MAT) due to fears of diversion, a concern Ostrovsky attributes to system failures (e.g., lack of reimbursement) rather than patient behavior.
• Only 60% of treatment facilities utilize MAT, with only 2% offering all three FDA-approved medications (methadone, buprenorphine, and naltrexone).
• Medicaid expansion is cited as an "easy win" policy lever that would immediately improve outcomes, yet many states still restrict access based on bias against low-income populations.
• Language reform is deemed essential; terms like "medication-assisted treatment" are considered stigmatizing because they imply the treatment is secondary to the cure, whereas the goal is to treat the chronic disease directly.

Funding, Research, and Data

• The $230 billion tobacco settlement is used as a cautionary tale, noting that 95% of funds were diverted to general state budgets (e.g., fixing potholes) rather than tobacco prevention.
• Current opioid settlement funds face similar uncertainty; there is no guarantee they will be directed to evidence-based programming or if states will prioritize addiction over general fiscal needs.
• Dr. Volkow launched an initiative in four high-mortality states (Massachusetts, Ohio, New York, Kentucky) to document whether integrated evidence-based interventions can reduce mortality by 50% within 18 months.
• Dr. Volkow plans to direct increased research funding toward understanding recovery support systems and reducing internalized stigma (self-depreciation) among patients.
• A study from the Johns Hopkins Stigma Lab indicates that narratives focusing on recovery improve stigma, whereas narratives linking recovery to reduced crime improve policy support but inadvertently worsen social stigma.

Clinical and Privacy Considerations

• Dr. Clark points out that return-to-work policies often demand permanent abstinence from patients, a standard not applied to other chronic diseases like epilepsy or diabetes, creating unnecessary barriers to employment.
• Michael Golinkoff and the panel discussed the paradox of privacy laws (42 CFR Part 2), which Dr. Clark argues institutionalize stigma by treating addiction data as more shameful than diabetes data, potentially hindering care coordination.
• The panel concludes that the current healthcare payment model undervalues addiction treatment compared to procedural interventions, disincentivizing providers from offering essential long-term care.